Innate Pharma S.A. ADR (IPHA) Stock Price, Quote & News

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 4 30 30 30 30

Fax: 33 4 30 30 30 00

Website: www.innate-pharma.com

Address:

117, Avenue de Luminy, BP 30191, Marseille, France

neo55 Mar. 13 at 1:39 AM

$IPHA BTIG assumes Innate Pharma at Buy rating and announces a price target of $8

0 · Reply

erevnon Mar. 12 at 11:25 AM

BTIG assumes Innate Pharma $IPHA at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

neo55 Mar. 10 at 8:49 PM

$IPHA Innate Pharma, the 2026 readout If PACIFIC-9 succeeds: • potential $500M+ milestone payments • long-term double-digit royalties 2-5 billion deals with $AZN 1-2 billion deal with $BMY 1-2 billion deal with $NVO Can 10 x overnight do research

0 · Reply

Billianas Mar. 10 at 8:34 PM

$IPHA this one is definitly going under 1$ and will face nasdaq compliance issues. You can buy it at discount around .50$ or less, just a matter of weeks. $XBI $IBB

0 · Reply

OfficialStocktwitsUser Feb. 28 at 3:04 AM

$IPHA RSI: 50.46, MACD: -0.0173 Vol: 0.05, MA20: 1.73, MA50: 1.75 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

6GodEnergy Feb. 23 at 5:39 PM

.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^

0 · Reply

wicklars Feb. 17 at 8:35 AM

$IPHA Pre-revenue biotech; early-stage

0 · Reply

peepthestamp Feb. 13 at 6:59 PM

$IPHA

0 · Reply

OfficialStocktwitsUser Feb. 2 at 11:47 PM

$IPHA RSI: 50.00, MACD: -0.0012 Vol: 0.03, MA20: 1.78, MA50: 1.81 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CapitalSignalMatrix Dec. 27 at 8:24 AM

$IPHA Investor attention is skewing toward repeatable operating performance instead of aspirational projections. Forecast reliability has room to improve materially. Credible progress tends to compress risk premiums. Momentum becomes sustainable only when delivery keeps pace.

0 · Reply

Market Cap	140.61M
Revenue (ttm)	21.77M
Net Income (ttm)	-53.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-245.89%
Debt to Equity Ratio	5.25

Volume	38,700
Avg Vol	19,412
Day's Range	N/A - N/A
Shares Out	93.74M
Stochastic %K	32%
Beta	-0.02
Analysts	Sell
Price Target	$3.50